-
Phase 1
-
-
18+Age Range
-
Active, Not Recruiting
Active, Not Recruiting
Trial of BMS-986012 in Combination With Platinum and Etoposide
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Male and Females 18 years of age or older - Pulmonary SCLC documented by histology or cytology - Extensive disease (Stage IV) SCLC - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Exclusion Criteria: - Prior systemic therapy for lung cancer - Symptomatic brain metastases - Grade 2 peripheral neuropathy - Active or chronic infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV - Other active malignancies or prior malignancy within 2 years Other protocol defined inclusion/exclusion criteria could apply
Active Comparator: Active Comparator Arm 3B
Experimental: Experimental Arm 1
Experimental: Experimental Arm 2
Experimental: Experimental Arm 3A
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information